Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, German Red Cross Blood Service Baden-Württemberg-Hessen, Heidelberg University, Mannheim, Germany.
J Mol Med (Berl). 2012 Jul;90(7):773-82. doi: 10.1007/s00109-012-0915-y. Epub 2012 May 31.
Due to their multi-lineage differentiation capacity, support of haematopoiesis, immunomodulation and secretion of proregenerative factors, mesenchymal stem/stromal cells (MSCs) are in the focus of intense research since decades. The literature is replete with reports on their potential in preclinical model systems. However, the heterogeneity of the primary cell population as starting material and the diverse protocols for isolation and cultivation are hampering progress in their clinical application. Consensus on common standards and harmonised isolation and characterisation protocols are important to ensure safety and efficacy. This review focuses on the recent scientific evidence of clinically relevant properties and on the speculative cardiomyogenic and hepatic differentiation potential of MSCs. Special emphasis is put on the importance of standardisation and harmonisation in clinical-scale manufacturing.
几十年来,间充质干细胞(MSCs)由于其多能分化能力、支持造血、免疫调节和分泌促修复因子的特性,一直是研究的热点。文献中充满了关于其在临床前模型系统中应用潜力的报告。然而,起始材料的原代细胞群体的异质性和分离及培养的不同方案阻碍了其临床应用的进展。关于共同标准和分离及鉴定方案的共识对于确保安全性和有效性非常重要。这篇综述重点介绍了最近关于间充质干细胞与临床相关特性和推测的心肌生成及肝分化潜能的科学证据。特别强调了在临床规模生产中标准化和协调的重要性。